Production of lactulose from lactose using a novel cellobiose 2-epimerase from Clostridium disporicum

IF 3.4 3区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Enzyme and Microbial Technology Pub Date : 2024-06-14 DOI:10.1016/j.enzmictec.2024.110466

Bohua Wang , Song Lei , Qingqin Li , Yushuang Luo

引用次数: 0

Abstract

Lactulose is a semisynthetic nondigestive sugar derived from lactose, with wide applications in the food and pharmaceutical industries. Its biological production routes which use cellobiose 2-epimerase (C2E) as the key enzyme have attracted widespread attention. In this study, a set of C2Es from different sources were overexpressed in Escherichia coli to produce lactulose. We obtained a novel and highly efficient C2E from Clostridium disporicum (CDC2E) to synthesize lactulose from lactose. The effects of different heat treatment conditions, reaction pH, reaction temperature, and substrate concentrations were investigated. Under the optimum biotransformation conditions, the final concentration of lactulose was up to 1.45 M (496.3 g/L), with a lactose conversion rate of 72.5 %. This study provides a novel C2E for the biosynthesis of lactulose from low-cost lactose.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利用一种来自双孔梭状芽孢杆菌的新型纤维生物糖 2-epimerase 从乳糖中生产乳纤维素

乳糖是一种从乳糖中提取的半合成非消化性糖类，在食品和制药行业有着广泛的应用。以纤维生物糖 2-酰亚胺酶（C2E）为关键酶的生物生产路线已引起广泛关注。本研究在大肠杆菌中过表达了一组不同来源的 C2E，以生产乳糖。我们从梭菌（Clostridium disporicum）中获得了一种新型、高效的 C2E（CDC2E），可从乳糖中合成乳糖。研究了不同热处理条件、反应 pH 值、反应温度和底物浓度的影响。在最佳生物转化条件下，乳糖的最终浓度可达 1.45 M（496.3 g/L），乳糖转化率为 72.5 %。这项研究为从低成本乳糖中生物合成乳糖提供了一种新型的 C2E。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Enzyme and Microbial Technology 生物-生物工程与应用微生物

CiteScore

7.60

自引率

5.90%

发文量

142

审稿时长

38 days

期刊介绍： Enzyme and Microbial Technology is an international, peer-reviewed journal publishing original research and reviews, of biotechnological significance and novelty, on basic and applied aspects of the science and technology of processes involving the use of enzymes, micro-organisms, animal cells and plant cells. We especially encourage submissions on: Biocatalysis and the use of Directed Evolution in Synthetic Biology and Biotechnology Biotechnological Production of New Bioactive Molecules, Biomaterials, Biopharmaceuticals, and Biofuels New Imaging Techniques and Biosensors, especially as applicable to Healthcare and Systems Biology New Biotechnological Approaches in Genomics, Proteomics and Metabolomics Metabolic Engineering, Biomolecular Engineering and Nanobiotechnology Manuscripts which report isolation, purification, immobilization or utilization of organisms or enzymes which are already well-described in the literature are not suitable for publication in EMT, unless their primary purpose is to report significant new findings or approaches which are of broad biotechnological importance. Similarly, manuscripts which report optimization studies on well-established processes are inappropriate. EMT does not accept papers dealing with mathematical modeling unless they report significant, new experimental data.